Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CNTX 
Context Therapeutics Inc (CNTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/17/2025: CNTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.33
1 Year Target Price $5.33
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.22% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 106.58M USD | Price to earnings Ratio - | 1Y Target Price 5.33 |
Price to earnings Ratio - | 1Y Target Price 5.33 | ||
Volume (30-day avg) 5 | Beta 1.94 | 52 Weeks Range 0.49 - 1.74 | Updated Date 11/16/2025 |
52 Weeks Range 0.49 - 1.74 | Updated Date 11/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.24 |
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.087 | Actual -0.1 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.81% | Return on Equity (TTM) -33.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 30700654 | Price to Sales(TTM) - |
Enterprise Value 30700654 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.6 | Shares Outstanding 91879177 | Shares Floating 39870969 |
Shares Outstanding 91879177 | Shares Floating 39870969 | ||
Percent Insiders 2.27 | Percent Institutions 75.36 |
Upturn AI SWOT
Context Therapeutics Inc
Company Overview
History and Background
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for hormone-driven cancers. Founded in 2015, the company's primary focus is on advancing its lead clinical candidate, onapristone extended release (ONA-XR), for the treatment of hormone-driven cancers.
Core Business Areas
- Pharmaceutical Development: Focuses on the research, development, and clinical trials of novel therapies for hormone-driven cancers. Their lead product is Onapristone Extended Release(ONA-XR).
Leadership and Structure
Martin Lehr serves as the Chief Executive Officer. The company operates with a core management team focused on clinical development, regulatory affairs, and business development. Board members include individuals with expertise in biotechnology and pharmaceutical industries.
Top Products and Market Share
Key Offerings
- Onapristone Extended Release (ONA-XR): ONA-XR is an investigational, Phase 2 product being evaluated for the treatment of hormone-driven cancers. Market share data is currently unavailable as the product is still under clinical development. Competition includes existing hormone therapies and emerging targeted therapies from companies like AstraZeneca (AZN) and Novartis (NVS).
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically oncology, is a large and growing market driven by aging populations and advancements in cancer treatment. The hormone-driven cancer segment is a significant sub-segment with unmet needs.
Positioning
Context Therapeutics is positioned as a company focused on novel approaches to treating hormone-driven cancers, specifically targeting the progesterone receptor. The ONA-XR has a competitive advantage is its targeted approach with a lower side effect profile that existing therapies.
Total Addressable Market (TAM)
The TAM for hormone-driven cancers is estimated to be billions of dollars annually. Context Therapeutics is focused on capturing a portion of this market with ONA-XR. As ONA-XR is still in development, it hasn't been introduced to the market as yet.
Upturn SWOT Analysis
Strengths
- Novel targeted therapy approach
- Experienced management team
- Strong intellectual property position
Weaknesses
- Limited financial resources
- Single product pipeline
- Clinical trial risks
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
Threats
- Competition from established therapies
- Regulatory hurdles
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- AstraZeneca (AZN)
- Novartis (NVS)
- Eli Lilly and Company (LLY)
Competitive Landscape
Context Therapeutics faces significant competition from established pharmaceutical companies. However, the company's novel approach and targeted therapy may provide a competitive advantage if clinical trials are successful.
Growth Trajectory and Initiatives
Historical Growth: Context Therapeutics' growth has been primarily focused on clinical development of its lead candidate. Historical growth is characterized by investment in R&D rather than revenue generation.
Future Projections: Future growth is highly dependent on successful clinical trial outcomes and potential commercialization or partnering opportunities. Analyst estimates are unavailable.
Recent Initiatives: Recent initiatives include advancing ONA-XR through ongoing clinical trials and exploring potential collaborations.
Summary
Context Therapeutics is a clinical-stage biopharmaceutical company focused on hormone-driven cancers, particularly through its lead product, ONA-XR. The company's strengths lie in its novel targeted therapy approach and an experienced management team. However, it is vulnerable due to limited financial resources and a single-product pipeline. Its future success depends on positive clinical trial outcomes, regulatory approval, and strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Context Therapeutics Inc. SEC Filings
- Company Website
- Press Releases
- Third-party financial databases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data may not be precise due to limited available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Context Therapeutics Inc
Exchange NASDAQ | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 2021-10-20 | Co-Founder, President, CEO & Director Mr. Martin A. Lehr | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | |
Full time employees 12 | |||
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.